Research Article
[Retracted] miR-100-5p Is a Novel Biomarker That Suppresses the Proliferation, Migration, and Invasion in Skin Cutaneous Melanoma
Table 1
The baseline clinical characteristics of TCGA-SKCM.
| Characteristic | Levels | Low expression of hsa-miR-100-5p | High expression of hsa-miR-100-5p | |
| Gender, (%) | Female | 84 (18.7%) | 88 (19.6%) | 0.771 | Male | 141 (31.3%) | 137 (30.4%) | |
| Age, (%) | ≤60 | 109 (24.7%) | 135 (30.5%) | 0.013 | >60 | 113 (25.6%) | 85 (19.2%) | |
| T stage, (%) | T1 | 21 (6.1%) | 17 (4.9%) | <0.001 | T2 | 31 (9%) | 48 (13.9%) | | T3 | 35 (10.1%) | 50 (14.5%) | | T4 | 93 (27%) | 50 (14.5%) | |
| N stage, (%) | N0 | 113 (28.3%) | 113 (28.3%) | 0.005 | N1 | 27 (6.8%) | 43 (10.8%) | | N2 | 20 (5%) | 29 (7.3%) | | N3 | 37 (9.3%) | 17 (4.3%) | |
| M stage, (%) | M0 | 197 (46.5%) | 203 (47.9%) | 0.513 | M1 | 14 (3.3%) | 10 (2.4%) | |
| Breslow depth, (%) | ≤3 | 74 (21.6%) | 106 (31%) | <0.001 | >3 | 100 (29.2%) | 62 (18.1%) | |
| Melanoma ulceration, (%) | No | 66 (22.1%) | 75 (25.1%) | 0.008 | Yes | 99 (33.1%) | 59 (19.7%) | |
| Melanoma Clark level, (%) | I | 2 (0.7%) | 4 (1.3%) | 0.003 | II | 9 (2.9%) | 8 (2.6%) | |
|
|